Association of TLR7 Variants with AIDS-Like Disease and AIDS Vaccine Efficacy in Rhesus Macaques

Roman A. Siddiqui¹,²*, Michael Krawczak³, Matthias Platzer², Ulrike Sauermann¹

¹ German Primate Center, Leibniz Institute for Primate Research, Göttingen, Germany, ² Genome Analysis, Leibniz Institute for Age Research–Fritz Lipmann Institute, Jena, Germany, ³ Institute of Medical Informatics and Statistics, Christian–Albrechts University, Kiel, Germany

Abstract

In HIV infection, TLR7-triggered IFN-α production exerts a direct antiviral effect through the inhibition of viral replication, but may also be involved in immune pathogenesis leading to AIDS. TLR7 could also be an important mediator of vaccine efficacy. In this study, we analyzed polymorphisms in the X-linked TLR7 gene in the rhesus macaque model of AIDS. Upon resequencing of the TLR7 gene in 36 rhesus macaques of Indian origin, 12 polymorphic sites were detected. Next, we identified three tightly linked single nucleotide polymorphisms (SNP) as being associated with survival time. Genotyping of 119 untreated, simian immunodeficiency virus (SIV)-infected male rhesus macaques, including an ‘MHC adjusted’ subset, revealed that the three TLR7 SNPs are also significantly associated with set-point viral load. Surprisingly, this effect was not observed in 72 immunized SIV-infected male monkeys. We hypothesize (i) that SNP c.13G>A in the leader peptide is causative for the observed genotype-phenotype association and that (ii) the underlying mechanism is related to RNA secondary structure formation. Therefore, we investigated a fourth SNP (c.-17C>T), located 17 bp upstream of the ATG translation initiation codon, that is also potentially capable of influencing RNA structure. In c.13A carriers, neither set-point viral load nor survival time were associated with the c.-17C>T genotype. In c.13G carriers, by contrast, the c.-17C allele was significantly associated with prolonged survival. Again, no such association was detected among immunized SIV-infected macaques. Our results highlight the dual role of TLR7 in immunodeficiency virus infection and vaccination and imply that it may be important to control human AIDS vaccine trials, not only for MHC genotype, but also for TLR7 genotype.

Introduction

Toll-like receptor 7 (TLR7) localizes to intracellular vesicles in antigen-presenting cells such as plasmacytoid dendritic cells, macrophages, memory B cells and T cells. In these cells, TLR7 functions as a receptor for pathogen recognition in that it binds ligands like uridine-rich single-stranded (ss) RNAs or certain small interfering RNAs [1,2,3,4]. Through the recognition of ssRNA derived from RNA viruses, TLR7 can also act as a danger receptor for viral infection (reviewed in [5,6,7]). Moreover, TLR7 activation modulates the innate and adaptive antiviral immune response by triggering the production of type I interferons, cytokines and chemokines [8,9]. The X-linked TLR7 gene appears to have been subject to positive selection during primate evolution, thereby underpinning its relevance in host-pathogen interaction [10].

TLR7 activation is an important mediator of vaccine efficacy. Targeting of TLR7 by synthetic agonists like polyU521, or conjugation of TLR7 to a protein vaccine, can prime high-frequency polyfunctional type 1 T helper cell (Th1) and cytotoxic T-lymphocyte (CTL) response, probably through the activation of plasmacytoid dendritic cells (PDC) [11,12,13]. The stimulation of Toll-like receptors, in particular TLR7, also appears to be a determinant of the greater magnitude and Th1 polarization of the immune response induced by inactivated whole-virus H5N1 influenza vaccine, as compared to split or subunit vaccine-induced responses [14]. Furthermore, IGA responses important for mucosal immunity potentially also depend upon TLR7 activation [15]. Targeting TLR7 may therefore improve vaccine efficacy.

In HIV infection, TLR7-triggered IFN-α production appears to be a double-edged sword [16]. On the one hand, stimulation of antigen-presenting cells by synthetic TLR7 agonists like imidazoquinoline compounds augment HIV-1-specific T cell responses in vitro [17]. Moreover, administration of IFN-α or triggering of TLR7/8 by imidazoquinoline compound R848 has direct anti-HIV effects by inhibiting viral replication in vitro, and potentially in vivo, through multiple pathways [18,19,20,21,22,23]. On the other hand, TLR7-triggered pathways appear to be directly involved in immune pathogenesis leading to AIDS [24,25]. Chronic immune stimulation via TLR7 in mice caused progressive lymphoid system destruction resembling HIV-mediated immunopathology [26]. Opposing effects of TLR7 have also been observed in the context of respiratory syncytial virus infection (RSV) in mice. Whereas administering TLR7/8 agonists during immunization did hardly influence the phenotype upon challenge with RSV, the immunostimulatory properties of the same agonists increased disease severity when used in mice that had already been infected [27]. Finally, since IFN-α production is particularly enhanced in females
upon TLR7 stimulation, the latter may also contribute to sex-specific disease progression [24,20].

The pathophysiological role of TLR7 can be studied in some detail in humans owing to a functional polymorphism located in the signal peptide. This Q11L amino acid replacement (rs1790068) has been shown to confer susceptibility to asthma [29] and to influence the course of hepatitis C infection [30], HIV disease progression and potentially HIV-1 acquisition [31]. Peripheral blood mononuclear cells (PBMCs) from individuals carrying the minor allele (11L) secreted less IFN-α upon stimulation by TLR7 agonist Imiquimod compared to PBMCs from individuals carrying the major allele [31]. Interestingly, the allele associated with diminished ex vivo IFN-α secretion was also associated with an accelerated time to onset of antiviral therapy (CD4 counts>350 μl) and higher set-point viral load in HIV-infected patients [31], indicating that the protective antiviral effects of TLR7 may prevail in the initial and chronic phases of infection.

The important role of TLR7 in viral infection and immunization prompted us to characterize TLR7 gene polymorphisms in simian immunodeficiency virus (SIV)-infected rhesus macaques (Macaca mulatta), which represent the most important animal model of HIV infection. Moreover, the expression patterns of TLR7 and other TLRs in antigen-presenting cells such as dendritic cells, monocytes and B cells are similar in macaques and humans, but differ markedly from the expression profiles in mice [32]. TLRs also respond to the same ligands in macaques as in humans [32]. Upon targeted TLR7 re-sequencing in 36 rhesus macaques of Indian origin, we detected 12 polymorphisms and subsequently investigated their possible association with AIDS-free survival and viremia in SIV-infected animals. We identified two polymorphisms, located immediately upstream and downstream of the TLR7 translation initiation codon, to be associated with survival time and/or set-point viral load in untreated SIV-infected macaques. Interestingly, no such association was evident in immunized-infected macaques.

**Results**

**Variability of the rhesus TLR7 gene**

Like in humans and many other species, the X-linked TLR7 gene in rhesus macaque contains three exons, namely two untranslated exons encompassing the 5′ untranslated region (5′UTR) and the ATG translation initiation codon, and exon 3 spanning the sequence coding for the leader peptide, the mature TLR7 polypeptide and a 3′ untranslated region (3′UTR) of about 1700 bp not yet annotated firmly in rhesus macaque. In contrast to the human situation, however, no polymorphisms in the rhesus TLR7 gene were known prior to this study. We therefore had to establish a panel of polymorphisms first before we could assess the impact of TLR7 gene variability upon the progression and outcome of SIV infection in this species.

Initial DNA sequence analysis of all three exons and some intronic parts of the TLR7 coding region, comprising a total of 7853 bp, was performed in a pilot sample 36 animals. Twelve variable positions were identified in the DNA sequence encoding the TLR7 mRNA (Figure S1), four of which were located in the protein-coding region of TLR7 (Figure S2). Two of the coding polymorphisms were non-synonymous whilst two were synonymous. The rhesus TLR7 amino acid sequence differs from human TLR7 by 19 amino acid substitutions (Figure S2). Notably, the amino acid sequences encoding the transmembrane and the Toll/IL-1 receptor (TIR) domain important for transport and associated signalling are identical in humans and rhesus macaques, and no polymorphisms were detected in these regions (Figure S2).

Seven of the eight non-coding polymorphisms were located in the 5′UTR of exon 3 whereas one was found in exon 2, 17 bp upstream of the ATG translation initiation codon. Since the rhesus genome is not yet annotated as thoroughly as the human genome, we provisionally labelled the SNPs following the recommendations for the description of DNA sequence variants made by the Human Genome Variation Society [33]. Allele frequencies observed among the 36 macaques of the pilot sample are given in Table 1.

Four single nucleotide polymorphisms (SNPs) were also genotyped in a larger sample. Thus, a total of 237 animals of Indian origin (46 females, 191 males), including the 36 samples used in the re-sequencing experiment, were investigated for SNPs c.-17C>T (5′UTR), c.13G>A (V5M), c.1710T>A (V570V) and c.*1604C>T (3′UTR). The last three polymorphisms were in strong pair-wise linkage disequilibrium (LD) in our sample (all pair-wise allelic r2>0.90) so that the respective allele frequencies were very similar (Table 1). Allele frequencies also differed hardly between the initial re-sequencing panel and the larger validation sample (data not shown).

**Association of TLR7 polymorphisms c.13G>A, c.1710T>A and c.*1604C>T with survival time and viral load in untreated SIV-infected rhesus macaques**

The initial re-sequencing experiment was carried out on 36 unrelated SIV-infected rhesus macaques that displayed the whole spectrum of disease progression (i.e., AIDS-free survival from 6 to >580 weeks post infection). Three of the discovered SNPs, namely c.13G>A, c.1710T>A, and c.*1604C>T, were suggestive of an association with survival time in the pilot sample. For further validation, a larger sample of 237 SIV-infected macaques was genotyped for the three SNPs either by Sanger sequencing or using a TaqMan-based allelic discrimination assay. In the following, we will only report upon c.13G>A, because the other two SNPs were in strong LD with this polymorphism (see above).

Among the 119 untreated-infected male macaques genotyped, AIDS-free survival was found to be significantly associated with the c.13G>A hemizygous status. Thus, male macaques carrying the minor allele (c.13A) progressed faster to AIDS than macaques carrying the major allele (c.13G). Log-rank X2 = 5.04, 1 d.f., p = 0.025 (Fig. 1A). Furthermore, c.13A carriers had a significantly higher viral load at set-point (F = 6.02, p = 0.011) (Fig. 2A).

**Table 1. Major allele frequencies (MAF) of 12 TLR7 gene polymorphisms in 36 rhesus macaques of Indian origin.**

<table>
<thead>
<tr>
<th>Polymorphism</th>
<th>Genomic Position</th>
<th>MAF</th>
</tr>
</thead>
<tbody>
<tr>
<td>c.17 C&gt;T</td>
<td></td>
<td>0.74</td>
</tr>
<tr>
<td>c.13 G&gt;A</td>
<td>(V5M)</td>
<td>0.68</td>
</tr>
<tr>
<td>c.204 A&gt;G</td>
<td>(T68A)</td>
<td>0.56</td>
</tr>
<tr>
<td>c.1710 T&gt;A</td>
<td>(V570V)</td>
<td>0.69</td>
</tr>
<tr>
<td>c.2352 G&gt;A</td>
<td>(R784R)</td>
<td>0.52</td>
</tr>
<tr>
<td>c.*437 G&gt;A</td>
<td></td>
<td>0.94</td>
</tr>
<tr>
<td>c.*236 A&gt;G</td>
<td></td>
<td>0.50</td>
</tr>
<tr>
<td>c.*867 T&gt;C</td>
<td></td>
<td>0.82</td>
</tr>
<tr>
<td>c.*908_1911 delGGCT</td>
<td></td>
<td>0.94</td>
</tr>
<tr>
<td>c.*941 A&gt;G</td>
<td></td>
<td>0.81</td>
</tr>
<tr>
<td>c.*1604 C&gt;T</td>
<td></td>
<td>0.69</td>
</tr>
<tr>
<td>c.*1681 A&gt;G</td>
<td></td>
<td>0.85</td>
</tr>
</tbody>
</table>

doi:10.1371/journal.pone.0025474.t001
No difference in peak viremia at week 2 post infection was observed, indicating that initial viral replication is not strongly influenced by c.13G>A genotype (F = 1.33, p = 0.252).

Since the MHC genotype is known to influence both survival time and viral load in HIV-infected humans as well as in SIV-infected macaques, we controlled our analysis for the presence for MHC genotypes known to strongly influence disease progression (Figure S3). Inspection of the data revealed that MHC genotypes previously found to be associated with either rapid or slow disease progression were not evenly distributed among the male animals studied here [34]. In the group of c.13A carriers, MHC genotypes associated with rapid disease progression were significantly overrepresented compared to c.13G carriers (17.1% vs. 2.4%; Fisher’s exact test p = 0.008) whereas MHC genotypes associated with slow disease progression [Mamu-A1*001, -B*008] were underrepresented (8.3% vs. 20.2%), although the second difference failed to reach statistical significance (Fisher’s exact test, p = 0.389). After excluding all of these animals from the analysis (‘MHC adjustment’), survival times were no longer significantly different between the two c.13G>A genotypes (log-rank χ² = 4.14, 1 d.f., p = 0.077) but still showed a trend towards longer survival being associated with c.13A (Fig. 1B). However, even in the smaller, MHC-adjusted sample comprising 63 monkeys, c.13A carriers still had a significantly higher set-point viral load than c.13G carriers (F = 6.02, p = 0.017) whilst peak viral load did not differ between genotypes (F = 0.61, p = 0.439).
We also investigated 28 untreated SIV-infected females available to seek evidence for a potential sex difference in terms of the observed genotype-phenotype relationship. Whilst only one female was homozygous for c.13A, c.AG heterozytes and c.GG homozygotes were almost equally frequent (13 vs. 14). The relevant MHC genotypes were evenly distributed between both groups and no significant difference in AIDS-free survival time was apparent between c.AG and c.GG females (log-rank \( \chi^2 = 0.155 \), 1 d.f., \( p = 0.694 \)). Further analyses were not deemed meaningful in view of the small sample size.

**TLR7 polymorphism at position −17 (c.-17C>T)**

influences set-point viral load and survival time in c.13G carriers

Polymorphisms close to the ATG start codon can affect translation initiation and thus the protein expression. We therefore

---

**Figure 2. Plasma RNA copy number at peak (2 wpi) and set-point (20 wpi) of SIV-infected male rhesus macaques, stratified by the TLR7 genotype.** Geometric mean and 95% confidence interval are indicated by error bars. Significant differences are marked by asterisks. A: untreated SIV-infected carriers of allele c.13A (n = 23) or c.13G (n = 54), and untreated SIV-infected monkeys after MHC adjustment carrying c.13A (n = 17) or c.13G (n = 46). B: untreated SIV-infected rhesus macaques stratified by their joint c.-17C>T and c.13G>A genotype: c.-17C,c.13A (n = 12), c.-17T,c.13A (n = 10), c.-17T,c.13G (n = 12), c.-17C,c.13G (n = 34). C: plasma RNA copy numbers of immunized SIV-infected macaques carrying c.13A or c.-17T,c.13G (n = 33), c.-17C,c.13G (n = 31), MHC adjusted: c.13A or c.-17T,c.13G (n = 20), c.-17C,c.13G (n = 18), carrying MHC alleles associated with slow disease progression: c.13A or c.-17T,c.13G (n = 11), c.-17C,c.13G (n = 10). 

doi:10.1371/journal.pone.0025474.g002
examined the potential effect of the c.-17C>T polymorphism, located in exon 2, which is not in linkage disequilibrium with the polymorphisms in exon 3. Exon 2 of the TLR7 gene is remarkably conserved between human and rhesus macaques, and no polymorphisms have been detected in the respective human sequence so far. Since the polymorphisms at position -17 and +13 might alter the local RNA secondary structure, we analyzed the phenotypic effect of the -17 polymorphism separately in both c.13A and c.13G males. Among the 34 c.13A carriers, the c.17C>T status was not significantly associated with either survival time, set-point viral load (both p>0.5) or peak viremia (p>0.1). From this analysis, only a single long-term non-progressing monkey carrying MmEu-A1*001 and B*017 was excluded because all other MHC genotypes were almost identically distributed within the two c.13G>A genotype-defined groups (Figures 1C, 2B). Note, however, that only MHC adjusted monkeys are shown in Figures 1C and 2B in order to allow direct comparison with Figures 1B and 2A. MHC adjustment reduced the number of monkeys analyzed but did not change the results of the statistical analysis.

In c.13G carriers, by contrast, the c.-17C>T polymorphism was significantly associated with survival time (log-rank $\chi^2 = 5.66$, 1 d.f., p = 0.017), but not with set-point or peak viral load (both p>0.5). Only MHC adjusted monkeys were included in this analysis because of the overrepresentation of slow progressor genotypes among c.-17C,c.13G carriers. Interestingly, survival time (p>0.6) and set-point viral load (p=0.1) did not differ significantly between c.13A and c.-17T,c.13G carriers, but between c.13A and c.-17C,c.13G carriers (survival time: log-rank $\chi^2 = 6.21$, 1 d.f., p = 0.013; set-point viral load: F = 8.10, p = 0.006). Thus, the inclusion of c.-17C>T genotype was capable of refining the genotype-phenotype association of c.13G>A. Eventually, only the c.-17C,c.13G haplotype turned to be significantly associated with prolonged survival and low set-point viral, compared to the other haplotypes (see Figures 1C, 2D).

No association of TLR7 polymorphisms with survival time and viral load in immunized SIV-infected macaques

Next, we analyzed the influence of the TLR7 SNPs upon AIDS-free survival and viral load in 72 immunized-infected male monkeys. These animals were analyzed separately because their survival time was significantly prolonged and their set-point viral load in immunized-infected female macaques compared to untreated-infected females (log-rank $\chi^2 = 3.91$, 1 d.f., p = 0.05). Although owing to the small sample size (n = 16), a detailed statistical analysis of the genotype-phenotype relationship was not considered warranted.

Prediction of RNA secondary structure

Since RNA secondary structure is a major determinant of translation kinetics and efficiency, we analyzed the potential effects upon RNA secondary structure of the SNPs associated with AIDS-free survival. Of the three tightly linked SNPs in exon 3, only c.13G>A, but not the two other SNPs, was found to influence RNA secondary structure (CentroidFold program) or to change the minimum free energy by more than $-2.1$ kcal/mol (RNAfold, Vienna WebSuite). For the signal peptide-encoding sequence (position 1–78), both prediction programs calculated an identical RNA secondary structure for the major c.13G allele, with a minimum free energy (MFE) of $-13.8$ kcal/mol (Fig. 3A). The c.13A allele disrupts this structure. The CentroidFold program predicted no strong secondary structure (MFE = 0 kcal/mol) at all for this sequence (Fig. 3B) whereas the Vienna RNA software predicted a secondary structure with an MFE of $-8.9$ kcal/mol. Despite some minor differences, both programs therefore suggested a destabilisation of the secondary structure of TLR7 signal peptide RNA sequence by the c.13A allele. The c.-17C>T polymorphism in exon 2 is located in a region critical for ribosomal entry and also influences RNA secondary structure. Both programs predict a stronger secondary structure for c.-17C compared to c.-17T containing RNA (MFE Centroidfold: $-12.7$ vs. 0 kcal/mol, RNAfold: $-20.2$ vs. $-17.6$ kcal/mol). Analyzing the effect of the c.-17C>T polymorphism in c.13A and c.13G carriers individually revealed that the folding effects of the two polymorphisms may be interdependent. CentroidFold predicted an MFE of $-39.7$ kcal/mol for the RNA sequence spanning exons 1 and 2 and the signal peptide-encoding region in the case of the c.-17C,c.13G haplotype whereas the structures of the other haplotypes had an MFE between $-30.0$ and $-29.1$ kcal/mol (Table 2). RNAfold predicted an MFE of $-51.5$ kcal/mol for the c.-17C,c.13G haplotype and of $-49.7$ to $-47.0$ kcal/mol for the other three haplotypes. Restriction of the in silico analysis to smaller RNA strands (25 bases up- and downstream of the c.-17 and c.13 position) yielded similar results (Table 2). Here, the c.-17C,c.13G haplotype also had the highest MFE, and the other haplotypes had a lower but relatively similar MFE. Despite some quantitative discrepancies, both programs therefore suggested (i) a joint effect of positions -17 and 13 on the RNA secondary structure and (ii) an RNA secondary structure that is most stable for the c.-17C,c.13G haplotype.

For comparison, we also analyzed the potential RNA secondary structure of the human TLR7 signal peptide-coding sequence. CentroidFold predicted an RNA secondary structure with an MFE of $0.0$ kcal/mol (Fig. 3C), whereas RNAfold predicted a structure with an MFE of $-10.2$ kcal/mol, indicating that the human TLR7 signal peptide-coding RNA structure is probably more similar to that of the rhesus c.13A allele. Both programs predicted that the Q11L (rs179008) polymorphism, which has been reported to influence viral load and time to AIDS in humans, does not influence the secondary structure of the human TLR7 signal peptide-coding RNA [31].
Finally, we investigated the influence, upon the potential RNA structure, of those SNPs that were not associated with AIDS-free survival in the initial sample of 36 macaques. The two remaining coding polymorphisms and three of the six polymorphisms in the 3’UTR did not change the predicted RNA secondary structure. The polymorphisms at position c.*236, c.*867 and the insertion/deletion c.*908_1911delGGCT changed the calculated MFE by more than 3 kcal/mol. None of polymorphisms in the 3’UTR was located close to a likely functional element [40]. Notably the polymorphisms at position c.*867 and c.*908_1911delGGCT flank the site of another functional polymorphism (TLR7 3’UTR SNP, rs3853839) reported in the human TLR7 gene [41].

**Discussion**

Prior to this study, no polymorphisms in the TLR7 gene locus of rhesus macaques were known. We therefore re-sequenced the TLR7 gene in 36 rhesus macaques of Indian origin and identified 12 polymorphisms. An initial analysis of 36 monkeys revealed three tightly linked SNPs to be associated with disease progression. Subsequent investigation of a larger sample of SIV-infected monkeys confirmed this initial result. The polymorphisms were significantly associated with viral load at set-point in untreated-SIV-infected male rhesus macaques and showed a trend towards an association with survival time even after the exclusion of monkeys carrying MHC alleles associated with rapid or slow disease progression. One of the polymorphisms of interest is located in the 3’UTR region of the TLR7 mRNA, one is a silent nucleotide substitution located at amino acid position 570, and the remaining variant encodes a non-synonymous amino acid substitution (5VM) in the leader peptide. Formally, we could not distinguish which of these tightly linked polymorphisms may be responsible for the differential viral load. Furthermore, each of the three types of genetic variation seen in TLR7 is known to affect protein expression. Mutations in the 3’UTR, for instance, can influence mRNA stability [42], silent mutations may influence translation efficiency and protein folding [43], and variations in the signal peptide can effect the transport, localization and synthesis of membrane-bound proteins [44,45,46].
The c.13G>A (V5M) SNP in the signal peptide represents a conservative exchange in the hydrophilic N-terminal region of the signal peptide. Using the SignalIP program [47], we found no evidence that the polymorphism would greatly influence processing of the signal peptide, although this cannot be ruled out completely without additional experimental evidence. In contrast, the 11L (rs179008) substitution in the human TLR7 signal peptide is potentially capable of altering signal peptide function (see supplement ref [44]). More convincing results were obtained in an analysis of RNA secondary structure. The rhesus c.13A allele very likely destabilizes an RNA secondary structure predicted for the c.13G allele. Interestingly, a strong RNA secondary structure comparable to the rhesus wild-type sequence was not predicted for the human TLR7 signal peptide RNA sequence, and it is unlikely that the Q11L (rs179008) polymorphism will affect the secondary structure of the signal peptide-encoding RNA sequence. Furthermore, neither the silent mutation at amino acid position 570 nor the substitution in the 3' UTR altered the potential secondary structure of the RNA around the respective SNPs. Based upon these predictions, the rhesus macaque c.13A allele is a functional candidate for the observed association with higher viral load in untreated-infected macaques [45,46]. This result encouraged us to also investigate the influence of an adjacent polymorphism at position −17, which may affect the same RNA structure and resides in a region critical for translation initiation. In silico analyses predicted that the effect of c.-17C>G upon RNA secondary structure was dependent upon the nucleotide present at position 13. Notably, c.-17C>G was associated with differential survival time only in c.13G carriers. Although translation represents a dynamic process that cannot be captured by mere sequence analyses, the coincidence of in silico prediction and experimental data therefore suggests that both SNPs exert a synergistic influence upon RNA structure.

It should be noted that, in whole genome screens involving human HIV-1-infected patients [48,49,50], the association between human TLR7 SNPs and disease progression did not attain statistical significance after Bonferroni correction. The validity of the respective associations has therefore been questioned [51]. While variation in the MHC region is undoubtedly the most important host factor for determining disease progression, however, it explains only a fraction of the variability in HIV viremia [48,49,50,52]. The identification of additional host gene polymorphisms contributing weakly to the variability of viremia or time to treatment initiation will require much larger cohorts and, because of the variability of the virus, the exact size of meaningful cohorts of HIV-1-infected patients may not even be known. We therefore proposed cross-species comparisons as a valuable means to validate potential host gene polymorphisms influencing the course of HIV-infection [53].

This report is the third one describing similar effects of co-localising functional genetic polymorphisms in humans and rhesus macaques even although the affected biochemical pathways may differ between the two species [53,54]. For TLR7, the rhesus substitution at position 13 and −17 are more likely to influence translation efficiency whereas the human Q11L variation probably influences transport or localization. At last, however, both variants would affect TLR7 expression.

Most interestingly, the TLR7 polymorphisms did not influence plasma viral set-point and survival time in immunized macaques. One explanation for this result could be that vaccination-induced immune reactions such as T and B cell response had a much stronger influence upon viral replication than differential TLR7 expression.

To better define the influence of TLR7 polymorphisms on vaccine efficacy, larger numbers of macaques treated with the same AIDS vaccine are required. Furthermore, it is paramount to investigate the exact contribution of the polymorphisms on TLR7 expression and cytokine secretion in vitro and in vivo, in untreated and infected, and in immunized subjects. Our work highlights the dual role of TLR7 in immunodeficiency virus infection and vaccination. Assuming that the c.13A and c.-17T,c.13G variants are associated with enhanced TLR7 expression, the data suggest that efficient triggering of TLR7 may improve AIDS vaccine efficacy while attenuating the action of TLR7 may decelerate disease progression. Finally, our results imply that it may be important to control human vaccine trials, not only for MHC genotype, but also for TLR7 genotype.
Materials and Methods

Animals and laboratory parameters

We retrospectively analyzed genetic and phenotypic data from 237 SIV-infected rhesus macaques (Macaca mulatta) of Indian origin, seronegative for STLV-1 and D-type virus. These animals were housed and treated at the German Primate Research Centre (‘Deutsches Primatenzentrum’, DPZ). All relevant protocols of the DPZ comply with the German Animal Protection Act, which in turn follows European Union guidelines on the use of non-human primates for biomedical research. This includes a 12:12 light dark schedule, provision of dry food supplemented with fresh fruit twice a day and constant water access. The monkeys were kept under permanent medical care. In cases of suffering monkeys were humanely killed. All experiments were approved by the independent governmental veterinary authority of Lower Saxony. Major characteristics of the monkeys under study and the algorithm used to define AIDS-like disease in these animals have been described before [53]. For the majority of samples viral RNA was isolated from frozen plasma samples following the MagAttract Virus Mini M48 protocol (Qiagen, Hilden, Germany). Purified SIV RNA was quantified using TaqMan-based real-time PCR on an ABI-Prism 7500 sequence detection system (Applied Biosystems) as described [55] using gag forward (5'-ACCAGTACAACAAATAGGTGG-TAACCT-3'), gag reverse primer (5'-TCAATTTTACCAGG-GATTATATGTGT-3') and a fluorescent labeled probe (5'-6FAM (6-carboxyfluorescein)-TGTCACCTGGCCATTAGCCCGAG-TAMRA (6-carboxytetramethylrhodamine)-3'). Amplified viral RNA was expressed as SIV-RNA copies per mL plasma. Samples from animals infected before 2004 were analyzed using another technique [56]. Peak and set-point viremia were quantified by the RNA viral copy number at weeks 2 and 20 post infection, respectively. If in addition data at week 24 post infection were available, the monkeys were reclassified as 'untreated' if they had not received any AIDS vaccine.

MHC-genotyping

Monkeys were genotyped for the MHC as described before and classified as either ‘slow progressor’, ‘rapid progressor’ or ‘unspecified’ [34]. Survival curves used as a guide for this ‘MHC adjustment’ of the subsequent statistical analyses are shown in Figure S3.

DNA sequence analysis of TLR7

Genomic DNA was isolated from peripheral blood or from Herpes papio virus-transformed B-cell lines using the Genomic DNA Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. The rhesus TLR7 gene was screened for polymorphisms by genomic re-sequencing of all three exons and parts of the flanking intron sequence in monkeys (chrX:10564627–10566043; chrX:10582811–10589400 in the former version, rehma2, still available at http://genome.usc.edu/cgi-bin/hgGateway). The primers used for nested PCR were designed using Primer3Plus [57] and are listed in Table S1. Between 25 and 50 ng of genomic DNA was used to generate the PCR template. Sequencing was performed using ABI Big Dye chemistry and the ABI3730x Analyzer (ABI, Foster City, Calif., USA). Overlapping amplicons were sequenced to ensure that no polymorphisms in the primer binding sites were missed. Polymorphisms were searched for with the GAP software (version 4.11 of the Staden package) using the implemented SNP candidate viewer, and by visual inspection. The DNA sequences of the re-sequenced genomic regions and the polymorphisms identified in these regions are deposited in GenBank (accession number JF691507).

Genotyping of TLR7

Three polymorphisms in the TLR7 gene were initially genotyped by means of Sanger sequencing. For amplifying the TLR7 c.13G>A substitution, we used primers TLR7-13-for (5’GG-AAAAATGCTGTCTTCTACATC and TLR7-13-rev (5’ATGG-CACGACCTGCTGTAAGGAGA); the silent c.1710T>A substitution was amplified with primers TLR7-1710-for (5’AGATATGGGC- CAGACCTGGA) and TLR7-1710-rev (5’TCAAAGGGCACGCTT ACCAA) and TLR7-1604-rev (5’CAAACCACGTACTTACTACCTCA). PCR was performed using 150 ng genomic DNA and included an initial denaturation step at 94°C for 5 min, followed by 30 cycles with a denaturation step at 94°C for 30 s, annealing at 57°C for 30 s, and elongation at 72°C. PCR products were either precipitated with ethanol or gel-purified using standard techniques (Qiagen, Hilden, Germany). DNA sequencing was performed using dye terminator chemistry and ABI 3730/3700 technology. DNA sequences were used to implement the CLUSTALW function of the Bioedit freeware (http://www.mbio.ncsu.edu/bioedit/bioedit.html).

Alternatively genotyping was performed by means of a Taq-Man-based allele discrimination assay (ABI7500 Real Time PCR System). The reaction volume of 25 μl contained 12.5 μl ImmoMix™ (Bioline, Luckenwalde, Germany), 660 nM ROX (Invitrogen, USA) as an internal standard, 90 nM of the respective primers, 20–24 nM labelled probes and 30 ng DNA. All samples were run in triplicates. PCR was performed with an initial denaturation step at 95°C for 10 min, a pre-read step at 60°C for 1 min, followed by denaturation at 92°C for 16 s and annealing/amplification for 1 min at the indicated temperature for 40 cycles and a post read step for 1 min in at 60°C. Primers and probes for detecting the c.13G>A polymorphism were: 13-forward (5’AAAAGAGGCCAGCAATGGGA), 13-reverse (5’AACCATCTAGCCCAGAGGTGT), and probes FAM-5’TTTCCAGTGTC- GACACTGAGAA-3’-BBQ (24 nm), annealing and amplification at 57°C. Oligonucleotides for detecting the c.1710T>A polymorphism were: 1710-forward (5’CAAGCAACCGGGTTTCA-TTTTACCCAGGAGTT), and probes FAM-5’-TTTCCAGTGTCGACACTGAGAA-3’-BBQ (24 nm, annealing and amplification at 57°C). For identification of the polymorphism at position c.*1604, we used 1604-forward (5’GGATGGAATGTAGAGGTCTG-3’), 1604-reverse (5’TACTGGATATAAGCAGT-BBQ (24 nm), and probes FAM-5’-TTGGAAGTTCTGATAAAGCAGT-3’-BBQ (20 nm) and YAK-5’-TTTCCAGTGGAACCAGCTTACGAGTAAAGCAGT-3’-BBQ (24 nm, annealing/amplification at 60°C). Oligonucleotides for detecting the c.*1604, we used 1604-forward (5’GGATGGAATGTAGAGGTCTG-3’), 1604-reverse (5’TACTGGATATAAGCAGT-BBQ (24 nm), and probes FAM-5’-TTGGAAGTTCTGATAAAGCAGT-3’-BBQ (20 nm) and YAK-5’-TTTCCAGTGGAACCAGCTTACGAGTAAAGCAGT-3’-BBQ (24 nm, annealing/amplification at 60°C).

Statistical analysis

Survival analysis was performed using the LIFETEST and LIFEREG procedures of the SAS software package (SAS version...
References


disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 27: 3045–3052.


